dr. mcdermott on lessons from the immotion150 trial in rcc
Published 7 years ago • 58 plays • Length 1:01Download video MP4
Download video MP3
Similar videos
-
1:42
dr. mcdermott on immotion150 trial in rcc
-
1:02
dr. mcdermott on novel immunotherapy combinations in rcc
-
2:07
dr. mcdermott on tki/immunotherapy combinations in rcc
-
1:33
dr. mcdermott on single-agent nivolumab in rcc
-
0:54
dr. mcdermott on immunotherapy as a standard of care in rcc
-
14:58
skin lymphoma hemepath/dermpath book! diagnosis of cutaneous lymphoid infiltrates by antonio subtil
-
2:21
mezigdomide: a novel celmod showing promise in the treatment of r/r myeloma
-
9:39
medullary thyroid cancer: things to know with mark e. zafareo, m.d.
-
6:02
second and third-line decisions in rcc
-
1:16
dr. mcdermott on toxicities of immunotherapy combinations in rcc
-
1:22
dr. mcdermott on major findings of efficacy and safety of nivolumab in rcc
-
1:53
dr. mcdermott on long-term benefit with nivolumab in rcc
-
1:38
dr. mcdermott on an analysis of the checkmate-214 study in rcc
-
0:45
dr. mcdermott on the role of vegf targeted therapy in rcc
-
2:18
dr. mcdermott on immunotherapy-related aes in rcc
-
1:24
dr. mcdermott on the use of anti–pd-1 combinations in mrcc
-
1:24
dr. mcdermott on nivolumab plus ipilimumab in rcc
-
1:09
dr. david f. mcdermott on nivolumab in rcc
-
1:10
dr. mcdermott on the promise of pembrolizumab in non-clear cell rcc
-
1:58
dr. mcdermott on single-agent pembrolizumab in advanced rcc
-
7:50
a look to the future in rcc
-
1:32
dr. mcgregor on the future of cabozantinib in rcc